- Home
- EQ vs ADXN Comparison
EQ vs ADXN Comparison
Compare EQ & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- ADXN
- Stock Information
- Founded
- EQ 2017
- ADXN 2002
- Country
- EQ United States
- ADXN Switzerland
- Employees
- EQ N/A
- ADXN N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- EQ Health Care
- ADXN Health Care
- Exchange
- EQ Nasdaq
- ADXN Nasdaq
- Market Cap
- EQ 12.2M
- ADXN 10.1M
- IPO Year
- EQ 2018
- ADXN N/A
- Fundamental
- Price
- EQ $0.41
- ADXN $8.37
- Analyst Decision
- EQ Buy
- ADXN Strong Buy
- Analyst Count
- EQ 3
- ADXN 1
- Target Price
- EQ $3.00
- ADXN $30.00
- AVG Volume (30 Days)
- EQ 519.6K
- ADXN 12.2K
- Earning Date
- EQ 08-07-2025
- ADXN 08-11-2025
- Dividend Yield
- EQ N/A
- ADXN N/A
- EPS Growth
- EQ N/A
- ADXN N/A
- EPS
- EQ N/A
- ADXN 0.10
- Revenue
- EQ $30,406,000.00
- ADXN $278,508.00
- Revenue This Year
- EQ N/A
- ADXN $86.57
- Revenue Next Year
- EQ N/A
- ADXN N/A
- P/E Ratio
- EQ N/A
- ADXN $0.74
- Revenue Growth
- EQ N/A
- ADXN N/A
- 52 Week Low
- EQ $0.27
- ADXN $6.51
- 52 Week High
- EQ $1.50
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- EQ 60.48
- ADXN 46.83
- Support Level
- EQ $0.29
- ADXN $7.52
- Resistance Level
- EQ $0.43
- ADXN $8.71
- Average True Range (ATR)
- EQ 0.06
- ADXN 0.43
- MACD
- EQ 0.01
- ADXN -0.14
- Stochastic Oscillator
- EQ 64.21
- ADXN 35.76
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.